Lilly’s soft tissue sarcoma treatment gets US approval
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly and Co’s treatment for adults with advanced soft tissue sarcoma (STS).
-
Former Toronto mayor dies of rare cancer: What is pleomorphic liposarcoma?
-
Teen fighting for her life after doctors mistake rare cancer for a pulled muscle
-
Roche’s lung cancer drug wins US approval
Lilly’s drug, Lartruvo, is approved for use with chemotherapy doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery. (http://bit.ly/2e6JNrz)
STS are cancers that develop in muscles, fat, tendons or other soft tissues.